DIVIDEND WITHHOLDING TAX UNDER THE CHINA-Switzerland TREATY (INDICATIVE)
10% — verify against the current DTA text and substance requirements before structuring.
Key points for investors from Switzerland
- Pharma: segment-production rules favor CDMO models
- R&D centers: new incentive stack
- Zurich talent routes via Shanghai
Swiss pharma, precision instruments and finance services fit the 2026 biotech and R&D-center openings. China-Switzerland FTA upgrade (2026) improves market access beyond the DTA.
Where we come in
Zhonghui Consulting has delivered numerous cross-border compliance engagements: WFOE registration, tax structuring, work permits, data compliance and exit planning — fixed fees, English-speaking delivery, ICPA-licensed review.
Start your China entry the compliant way
Free 30-minute diagnosis · fixed-fee packages · English delivery team.
Start with a Free Diagnosis →General information only — not legal, tax, or investment advice. Tax-treaty rates shown are indicative; always verify against the current double-tax-arrangement text and official sources (SAMR, STA, SAFE, MOFCOM, NDRC) with licensed advisors.